 |
 |
NHS Bath and North East Somerset, Swindon and Wiltshire CCG
Royal United Hospitals Bath NHS Foundation Trust
Great Western Hospitals NHS Foundation Trust
Salisbury NHS Foundation Trust
|
| Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
Notes:
Hameatology/Oncology related Prescribing Guidance
Please see our Prescribing Guidelines page for all prescribing guidance relating to this chapter.
Haematology/Oncology related Shared Care Agreements
Please see our Shared Care Agreements page for all shared care agreements (SCAs) relating to this chapter.
|
|
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
08.01 |
Cytotoxic drugs
(0,2)
|
|
|
Drugs for cytotoxic-induced side-effects
(3,2)
|
|
08.01.01 |
Alkylating drugs
(10,4)
|
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(10,0)
|
|
08.01.03 |
Antimetabolites
(12,2)
|
|
08.01.04 |
Vinca alkaloids and etoposide
(7,0)
|
|
08.01.05 |
Other antineoplastic drugs
(29,5)
|
|
|
Amsacrine
(1,0)
|
|
|
Arsenic trioxide
(1,0)
|
|
|
Bortezomib
(1,0)
|
|
|
Brentuximab vedotin
(1,0)
|
|
|
Cetuximab
(1,0)
|
|
|
Dacarbazine and Temozolomide
(2,0)
|
|
|
Erlotinib
(1,0)
|
|
|
Hydroxycarbamide
(1,0)
|
|
|
Ipilimumab
(1,0)
|
|
|
Pentostatin
(1,0)
|
|
|
Platinum compounds
(3,1)
|
|
|
Procarbazine
(1,0)
|
|
|
Protein kinase inhibitors
(16,0)
|
|
|
Taxanes
(4,0)
|
|
|
Topoisomerase I inhibitors
(3,0)
|
|
|
Trabectedin
(1,0)
|
|
|
Trastuzumab
(3,0)
|
|
|
Tretinoin
(1,0)
|
|
|
Vismodegib
(0,1)
|
|
08.02 |
Drugs affecting the immune response
(1,0)
|
|
08.02.01 |
Antiproliferative immunosuppressants
(2,1)
|
|
08.02.02 |
Corticosteroids and other immunosuppressants
(5,3)
|
|
08.02.03 |
Anti-lymphocyte monoclonal antibodies
(5,0)
|
|
08.02.04 |
Other immunomodulating drugs
(13,1)
|
|
|
Interferon Alfa
(2,1)
|
|
|
Interferon beta
(4,0)
|
|
|
Glatiramer acetate
(1,0)
|
|
|
Lenalidomide, pomalidomide, and thalidomide
(1,0)
|
|
|
Mifamurtide
(1,0)
|
|
|
Natalizumab
(1,0)
|
|
08.03 |
Sex hormones and hormone antagonists in malignant disease
(0,0)
|
|
08.03.01 |
Oestrogens
(1,1)
|
|
08.03.02 |
Progestogens
(3,0)
|
|
08.03.03 |
Androgens
(0,0)
|
|
08.03.04 |
Hormone antagonists
(0,0)
|
|
08.03.04.01 |
Breast cancer
(6,2)
|
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues
(1,1)
|
|
|
Gonadorelin analogues
(1,0)
|
|
|
Anti-androgens
(8,1)
|
|
08.03.04.03 |
Somatostatin analogues
(4,0)
|
|
|
|
